Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

The European Commission (EC) on Friday approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fred Hutch Cancer Center medical oncologist Dr. Lisa Tachiki has been named a 2025 Cancer Research Fellow by the Kuni Foundation, an honor that includes an unrestricted, two-year $300,000 award.

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...

Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026; Lorigerlimab Phase 2 LINNET study update in mid-2026; IN ...

YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40 ...